ABSTRACT
Background and Aims APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that are actively pursued as pharmacological targets to treat dyslipidemia and reduce the risk of atherosclerotic cardiovascular disease. Here, we used human genetic data to compare the predicted therapeutic and adverse effects of APOC3, ANGPTL3, and ANGPTL4 inactivation.
Methods We conducted drug-target Mendelian randomization analyses using variants in proximity to the genes associated with circulating protein levels to compare APOC3, ANGPTL3, and ANGPTL4 as drug targets. We obtained exposure and outcome data from large-scale genome-wide association studies and used generalized least squares to correct for linkage disequilibrium-related correlation. We evaluated six primary cardiometabolic endpoints and screened for potential side effects across 694 disease-related endpoints, 43 clinical laboratory tests, and 11 internal organ MRI measurements.
Results Genetically lowering circulating ANGPTL4 levels reduced the odds of coronary artery disease (CAD) (odds ratio, 0.57 per s.d. protein [95%CI,0.47–0.70]) and type 2 diabetes (T2D) (odds ratio, 0.73 per s.d. protein [95%CI,0.57–0.94]). Genetically lowering circulating APOC3 levels also reduced the odds of CAD (odds ratio, 0.90 per s.d. protein [95%CI,0.82–0.99]). Genetically lowered ANGPTL3 levels via common variants were not associated with CAD. However, meta-analysis of loss-of-function variants revealed that ANGPTL3 inactivation protected against CAD (odds ratio, 0.71 per allele [95%CI,0.62–0.82]). Analysis of lowered ANGPTL3, ANGPTL4, and APOC3 levels did not identify important safety concerns.
Conclusion Human genetic evidence suggests that therapies aimed at reducing circulating levels of ANGPTL3, ANGPTL4, and APOC3 reduce the risk of CAD. ANGPTL4 lowering may also reduce the risk of T2D.
STRUCTURED GRAPHICAL ABSTRACT Key Question: Does human genetics support that triglyceride-lowering drugs targeting ANGPTL3, ANGPTL4, and APOC3 will reduce the risk of cardiometabolic disease without causing side effects?
Key Finding: Genetically lowered circulating ANGPTL4 reduced coronary artery disease and type 2 diabetes risk. Genetically lowered ANGPTL3 and APOC3 also reduced coronary artery disease risk, but no impact on type 2 diabetes risk was observed.
Take-home Message: Human genetics suggest that ANGPTL3, ANGPTL4, and APOC3-lowering medications may prevent CAD. Medicines targeting ANGPTL4 may have added benefits for patients with type 2 diabetes.
Competing Interest Statement
F.L. is a part-time employee of Lipigon Pharmaceuticals AB. S.K.N. is the chief executive officer of Lipigon. S.K. is a paid consultant for Lipigon.
Funding Statement
This research received no specific grants from public or non-profit funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used GWAS summary statistics that were originally located at: https://www.decode.com/summarydata/, https://azphewas.com, http://www.nealelab.is/uk-biobank/, http://ckdgen.imbi.uni-freiburg.de/files/Stanzick2021/metal_eGFR_meta_ea1.TBL.map.annot.gc.gz, http://ckdgen.imbi.uni-freiburg.de/files/Stanzick2021/metal_eGFRcys_meta1.TBL.map.annot.gc.gz, https://www.ebi.ac.uk/gwas/studies/GCST90132314, http://www.diagram-consortium.org/downloads.html, http://ckdgen.imbi.uni-freiburg.de/files/Wuttke2019/CKD_overall_EA_JW_20180223_nstud23.dbgap.txt.gz, https://www.ebi.ac.uk/gwas/studies/GCST90091033, https://www.ebi.ac.uk/gwas/studies/GCST006624, https://www.ebi.ac.uk/gwas/studies/GCST006630, https://zenodo.org/record/1251813/files/bmi.giant-ukbb.meta-analysis.combined.23May2018.txt.gz, https://zenodo.org/record/1251813/files/whr.giant-ukbb.meta-analysis.combined.23May2018.txt.gz, https://zenodo.org/record/1251813/files/whradjbmi.giant-ukbb.meta-analysis.combined.23May2018.txt.gz, https://gwas.mrcieu.ac.uk/files/ukb-b-8909/ukb-b-8909.vcf.gz, https://www.ebi.ac.uk/gwas/studies/GCST90016673, https://www.ebi.ac.uk/gwas/studies/GCST90016666, https://www.ebi.ac.uk/gwas/studies/GCST90016667, https://www.ebi.ac.uk/gwas/studies/GCST90016671, https://www.ebi.ac.uk/gwas/studies/GCST90016672, https://www.ebi.ac.uk/gwas/studies/GCST90016674, https://www.ebi.ac.uk/gwas/studies/GCST90016675, https://www.ebi.ac.uk/gwas/studies/GCST90016670, https://www.ebi.ac.uk/gwas/studies/GCST90016668, https://www.ebi.ac.uk/gwas/studies/GCST90016669, https://www.ebi.ac.uk/gwas/studies/GCST90016676, https://gwas.mrcieu.ac.uk/datasets/, https://public-metaresults-fg-ukbb.finngen.fi/, https://r8.finngen.fi/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.